Recently, the anti-melanoma differentiation-associated gene 5 (MDA-5) antibody was demonstrated to be involved in DM and reflect the response to treatment and outcome of CADM-associated RPIPs [3–5]. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.